Our Mission
Our mission is to generate therapeutic antibodies to novel cancer targets and develop new cancer drugs to provide meaningful treatments and cures for patients with aggressive and metastatic cancers.
Boston-based Biotech
We are developing a new Antibody and Antibody-Drug-Conjugate (ADC) therapeutics to treat and cure patients suffering from solid tumor and metastatic disease.
Targeted-Cancer Drug Development Strategy
Our targeted cancer drug development strategy is based on our belief that the solution to making better cancer drugs is to find better novel cancer targets. We develop antibodies and ADCs to novel embryonic cancer targets - targets expressed in metastatic and aggressive cancers but not in normal healthy tissues. Big picture: We believe cancer is an embryonic disease ( In scientific terms, a disease caused by epigenetic reprogramming/de-differentiation of a normal cell into a rouge malignant cancer cell with embryonic stem cell properties).
Antibody
We have developed a proprietary antibody platform and have generated a robust pipeline of antibodies to novel cancer targets. Our lead cancer drug, CM-14 is a First-in-Class Humanized ADC to treat patients with pancreatic and gastric cancers.
Next Steps
We are transitioning from a preclinical to a clinical biotech and preparations are underway to take CM-14 into a human clinical cancer trial.
To learn more about CureMeta and our lead ADC asset please review the
non-confidential deck below:
CureMeta Overview 2024